News
Ozempic, a drug known for its physical health benefits, is now gaining recognition for its effectiveness in treating ...
Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.
With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...
The Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infringement case filed by Bristol Myers Squibb concerning its ...
A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...
Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results